BioSpace News Archive

Drug discovery services market is slated to witness strong growth prospects in the global market, reaching an estimation of US$ 16,800.1 million in terms of revenue by 2026 end, according to a new study by Fact.MR.

According to a recent research report published by Fact.MR, the global basal cell carcinoma treatment market is expected to witness a highly promising growth opportunity in the coming years of the forecast period ranging from 2020 to 2025.

The global immunohistochemistry market is projected to expand at a healthy pace. Factors responsible for the growth of this market include growing geriatric population, high prevalence of chronic diseases, and rise in the number of diagnostic centers.

The development of the healthcare industry and the introduction of new drugs and therapeutics are the key factors estimated to encourage the growth of the global PEGylated proteins market in the next few years.

Tiziana Life Sciences plc, a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer.

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, announced that it has raised EUR 127 million in Series B financing.

Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, announced certain preliminary unaudited fourth quarter and full year 2020 revenue results.

The extraordinary general meeting in Medivir Aktiebolag on 13 January 2021 resolved, in accordance with the board of directors’ proposal, to decrease the company’s share capital with SEK 20,908,234.356976 without cancellation of shares.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, and UT Southwestern Medical Center (UTSW) today announced the launch of an innovation fund

LumiraDx, the next generation point-of-care diagnostic company, announced that the Scandinavian evaluation of laboratory equipment for point of care testing had published a positive evaluation of the LumiraDx SARS-CoV-2 Antigen Test.